Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA.
Center for Neural Circuits and Behavior, Department of Neuroscience and Section for Neurobiology, Division of Biology, University of California at San Diego, San Diego, CA 92093-0634, USA.
Biochem Pharmacol. 2019 Jan;159:140-153. doi: 10.1016/j.bcp.2018.11.018. Epub 2018 Nov 29.
N-methyl-d-aspartate receptors (NMDARs) have multiple prominent roles in CNS function but their excessive or insufficient activity contributes to neuropathological/psychiatric disorders. Consequently, a variety of positive and negative allosteric modulators (PAMs and NAMs, respectively) have recently been developed. Although these modulators bind to extracellular domains, in the present report we find that the NMDAR's intracellular C-terminal domains (CTDs) significantly influence PAM/NAM activity. GluN2 CTD deletion robustly affected NAM and PAM activity with both enhancing and inhibiting effects that were compound-specific and NMDAR subunit-specific. In three cases, individual PAMs became NAMs at specific GluN2-truncated receptors. In contrast to GluN2, GluN1 CTD removal only reduced PAM activity of UBP684 and CIQ, and did not affect NAM activity. Consistent with these findings, agents altering phosphorylation state or intracellular calcium levels displayed receptor-specific and compound-specific effects on PAM activity. It is possible that the GluN2's M4 domain transmits intracellular modulatory signals from the CTD to the M1/M4 channel gating machinery and that this site is a point of convergence in the direct or indirect actions of several PAMs/NAMs thus rendering them sensitive to CTD status. Thus, allosteric modulators are likely to have a marked and varied sensitivity to post-translational modifications, protein-protein associations, and intracellular ions. The interaction between PAM activity and NMDAR CTDs appears reciprocal. GluN1 CTD-deletion eliminated UBP684, but not pregnenolone sulfate (PS), PAM activity. And, in the absence of agonists, UBP684, but not PS, was able to promote movement of fluorescently-tagged GluN1-CTDs. Thus, it may be possible to pharmacologically target NMDAR metabotropic activity in the absence of channel activation.
N-甲基-D-天冬氨酸受体(NMDARs)在中枢神经系统功能中具有多种重要作用,但它们的过度或不足活动会导致神经病理学/精神疾病。因此,最近开发了多种正变构调节剂(PAMs)和负变构调节剂(NAMs)。尽管这些调节剂结合在细胞外结构域,但在本报告中,我们发现 NMDAR 的细胞内 C 端结构域(CTDs)显著影响 PAM/NAM 活性。GluN2 CTD 缺失强烈影响 NAM 和 PAM 活性,具有增强和抑制作用,且具有化合物特异性和 NMDAR 亚基特异性。在三种情况下,个别 PAMs 在特定的 GluN2 截断受体上成为 NAMs。与 GluN2 不同,GluN1 CTD 缺失仅降低了 UBP684 和 CIQ 的 PAM 活性,而不影响 NAM 活性。与这些发现一致,改变磷酸化状态或细胞内钙水平的试剂对 PAM 活性表现出受体特异性和化合物特异性作用。可能是 GluN2 的 M4 结构域将细胞内调节信号从 CTD 传递到 M1/M4 通道门控机械结构,并使该位点成为几种 PAMs/NAMs 的直接或间接作用的交汇点,从而使它们对 CTD 状态敏感。因此,变构调节剂可能对翻译后修饰、蛋白质-蛋白质相互作用和细胞内离子具有显著且不同的敏感性。PAM 活性与 NMDAR CTDs 之间的相互作用似乎是相互的。GluN1 CTD 缺失消除了 UBP684,但不消除孕烯醇酮硫酸盐(PS)的 PAM 活性。并且,在没有激动剂的情况下,UBP684,但不是 PS,能够促进荧光标记的 GluN1-CTDs 的运动。因此,在没有通道激活的情况下,有可能对 NMDAR 代谢型活性进行药理学靶向。